



PHARMACOLOGIC PRODUCT GUIDE: FIRST-LINE MEDICATIONS

| NICOTINE REPLACEMENT THERAPY (NRT) FORMULATIONS | | | | | | | | BUPROPION SR |
|---|--|--|--|---|--|---|--|---|
| | GUM | LOZENGE | TRANSDERMAL PREPARATIONS | | | NASAL SPRAY | ORAL INHALER | |
| PRODUCT | Nicorette ¹ , Generic OTC 2 mg, 4 mg; regular, mint, FreshMint ¹ , orange ¹ | Commit ¹ OTC 2 mg, 4 mg | Nicotrol Patch ² OTC 16-hour release 5 mg, 10 mg, 15 mg | Nicoderm CQ ¹ OTC 24-hour release 7 mg, 14 mg, 21 mg | Generic Patch OTC/Rx (formerly Habitrol) 24-hour release 7 mg, 14 mg, 21 mg | Nicotrol NS ² Rx Metered spray 0.5 mg nicotine in 50 µL aqueous nicotine solution | Nicotrol Inhaler ² Rx 10 mg cartridge delivers 4 mg inhaled nicotine vapor | Zyban ¹ , Generic Rx 150 mg sustained-release tablet |
| PRECAUTIONS | <ul style="list-style-type: none"> ▪ Pregnancy (Category D) ▪ Recent (≤ 2 weeks) myocardial infarction ▪ Serious underlying arrhythmias ▪ Serious or worsening angina pectoris ▪ Temporomandibular joint disease | <ul style="list-style-type: none"> ▪ Pregnancy (Category D) ▪ Recent (≤ 2 weeks) myocardial infarction ▪ Serious underlying arrhythmias ▪ Serious or worsening angina pectoris | <ul style="list-style-type: none"> ▪ Pregnancy (Category D) ▪ Recent (≤ 2 weeks) myocardial infarction ▪ Serious underlying arrhythmias ▪ Serious or worsening angina pectoris | | | <ul style="list-style-type: none"> ▪ Pregnancy (Category D) ▪ Recent (≤ 2 weeks) myocardial infarction ▪ Serious underlying arrhythmias ▪ Serious or worsening angina pectoris ▪ Underlying chronic nasal disorders (rhinitis, nasal polyps, sinusitis) ▪ Severe reactive airway disease | <ul style="list-style-type: none"> ▪ Pregnancy (Category D) ▪ Recent (≤ 2 weeks) myocardial infarction ▪ Serious underlying arrhythmias ▪ Serious or worsening angina pectoris ▪ Bronchospastic disease | <ul style="list-style-type: none"> ▪ Pregnancy (Category B) ▪ Concomitant therapy with medications or medical conditions known to lower the seizure threshold <p>Contraindications:</p> <ul style="list-style-type: none"> ▪ Seizure disorder ▪ Hx of bulimia or anorexia nervosa ▪ MAO inhibitor therapy in previous 14 days ▪ Concomitant bupropion (e.g., Wellbutrin) therapy ▪ Simultaneous abrupt discontinuation of alcohol or sedatives |
| DOSING | <p>≥ 25 cigarettes/day: 4 mg < 25 cigarettes/day: 2 mg</p> <p>Week 1–6: 1 piece q 1–2 hours Week 7–9: 1 piece q 2–4 hours Week 10–12: 1 piece q 4–8 hours</p> <ul style="list-style-type: none"> ▪ Maximum, 24 pieces/day ▪ Chew each piece slowly ▪ Park between cheek and gum when peppery, minty, or citrus taste or tingling sensation appears (~15–30 chews) ▪ Resume chewing when taste or tingle fades ▪ Repeat chew/park steps until most of the nicotine is gone (taste or tingle does not return; generally 30 min) ▪ Park in different areas of mouth ▪ No food or beverages 15 min before or during use ▪ Duration: up to 12 weeks | <p><i>1st cigarette ≤ 30 minutes after waking:</i> 4 mg <i>1st cigarette > 30 minutes after waking:</i> 2 mg</p> <p>Week 1–6: 1 lozenge q 1–2 hours Week 7–9: 1 lozenge q 2–4 hours Week 10–12: 1 lozenge q 4–8 hours</p> <ul style="list-style-type: none"> ▪ Maximum, 20 lozenges/day ▪ Allow to dissolve slowly (20–30 minutes) ▪ Nicotine release may cause a warm, tingling sensation ▪ Do not chew or swallow ▪ Occasionally rotate to different areas of the mouth ▪ No food or beverages 15 minutes before or during use ▪ Duration: up to 12 weeks | <p><u>> 10 cigarettes/day:</u> 15 mg/day x 6 weeks 10 mg/day x 2 weeks 5 mg/day x 2 weeks</p> <p><u>≤ 10 cigarettes/day:</u> NOT recommended</p> <ul style="list-style-type: none"> ▪ Remove at bedtime ▪ Duration: 10 weeks | <p><u>> 10 cigarettes/day:</u> 21 mg/day x 6 weeks 14 mg/day x 2 weeks 7 mg/day x 2 weeks</p> <p><u>≤ 10 cigarettes/day:</u> 14 mg/day x 6 weeks 7 mg/day x 2 weeks</p> <ul style="list-style-type: none"> ▪ May wear patch for 16 hours if patient experiences sleep disturbances (remove at bedtime) ▪ Duration: 8–10 weeks | <p><u>> 10 cigarettes/day:</u> 21 mg/day x 4 weeks 14 mg/day x 2 weeks 7 mg/day x 2 weeks</p> <p><u>≤ 10 cigarettes/day:</u> 14 mg/day x 6 weeks 7 mg/day x 2 weeks</p> <ul style="list-style-type: none"> ▪ May wear patch for 16 hours if patient experiences sleep disturbances (remove at bedtime) ▪ Duration: 8 weeks | <p>1–2 doses/hour (8–40 doses/day) One dose = 2 sprays (one in each nostril); each spray delivers 0.5 mg of nicotine to the nasal mucosa</p> <ul style="list-style-type: none"> ▪ Maximum <ul style="list-style-type: none"> – 5 doses/hour – 40 doses/day ▪ For best results, initially use at least 8 doses/day ▪ Patients should not sniff, swallow, or inhale through the nose as the spray is being administered ▪ Gradually decrease usage over 3–6 months ▪ Duration: 3–6 months | <p>6–16 cartridges/day; individualized dosing</p> <ul style="list-style-type: none"> ▪ Initially, use at least 6 cartridges/day ▪ Best effects with continuous puffing for 20 minutes ▪ Nicotine in cartridge is depleted after 20 minutes of active puffing ▪ Patient should inhale into back of throat or puff in short breaths. ▪ Do NOT inhale into the lungs (like a cigarette) but “puff” as if lighting a pipe. ▪ Open cartridge retains potency for 24 hours ▪ Duration: up to 6 months | <p>150 mg po q AM x 3 days, then increase to 150 mg po bid</p> <ul style="list-style-type: none"> ▪ Do NOT exceed 300 mg/day ▪ Treatment should be initiated while patient is still smoking ▪ Set quit date 1–2 weeks after initiation of therapy ▪ Allow at least 8 hours between doses ▪ Avoid bedtime dosing to minimize insomnia ▪ Dose tapering is NOT necessary ▪ Can be used safely with NRT ▪ Duration: 7–12 weeks after quit date (maintenance up to 6 months) |

| NICOTINE REPLACEMENT THERAPY (NRT) FORMULATIONS | | | | | | | | |
|---|--|---|---|--|---|--|--|---|
| | GUM | LOZENGE | TRANSDERMAL NICOTINE PREPARATIONS | | | NASAL SPRAY | ORAL INHALER | BUPROPION SR |
| | | | NICOTROL | NICODERM CQ | GENERIC PATCH (FORMERLY HABITROL) | | | |
| ADVERSE EFFECTS | <ul style="list-style-type: none"> ▪ Mouth/jaw soreness ▪ Hiccups ▪ Dyspepsia ▪ Hypersalivation ▪ Effects associated with incorrect chewing technique: <ul style="list-style-type: none"> – Lightheadedness – Nausea/vomiting – Throat and mouth irritation | <ul style="list-style-type: none"> ▪ Nausea ▪ Hiccups ▪ Cough ▪ Heartburn ▪ Headache ▪ Flatulence ▪ Insomnia | <ul style="list-style-type: none"> ▪ Local skin reactions (erythema, pruritus, burning) ▪ Headache | <ul style="list-style-type: none"> ▪ Local skin reactions (erythema, pruritus, burning) ▪ Headache ▪ Sleep disturbances (insomnia) or abnormal/vivid dreams (associated with nocturnal nicotine absorption) | | <ul style="list-style-type: none"> ▪ Nasal and/or throat irritation (hot, peppery, or burning sensation) ▪ Rhinitis ▪ Tearing ▪ Sneezing ▪ Cough ▪ Headache | <ul style="list-style-type: none"> ▪ Mouth and/or throat irritation ▪ Unpleasant taste ▪ Cough ▪ Rhinitis ▪ Dyspepsia ▪ Hiccups ▪ Headache | <ul style="list-style-type: none"> ▪ Insomnia ▪ Dry mouth ▪ Nervousness/difficulty concentrating ▪ Rash ▪ Constipation ▪ Seizures (risk is 1/1,000 [0.1%]) |
| ADVANTAGES | <ul style="list-style-type: none"> ▪ Gum use might satisfy oral cravings ▪ Gum use may delay weight gain ▪ Patients can titrate therapy to manage withdrawal symptoms | <ul style="list-style-type: none"> ▪ Lozenge use might satisfy oral cravings ▪ Patients can titrate therapy to manage withdrawal symptoms | <ul style="list-style-type: none"> ▪ Provides consistent nicotine levels over 16 hours ▪ Easy to use and conceal ▪ Once-a-day dosing associated with fewer compliance problems | <ul style="list-style-type: none"> ▪ Provides consistent nicotine levels over 24 hours ▪ Easy to use and conceal ▪ Once-a-day dosing associated with fewer compliance problems | <ul style="list-style-type: none"> ▪ Provides consistent nicotine levels over 24 hours ▪ Easy to use and conceal ▪ Once-a-day dosing associated with fewer compliance problems | <ul style="list-style-type: none"> ▪ Patients can titrate therapy to manage withdrawal symptoms | <ul style="list-style-type: none"> ▪ Patients can titrate therapy to manage withdrawal symptoms ▪ Mimics hand-to-mouth ritual of smoking | <ul style="list-style-type: none"> ▪ Easy to use; oral formulation associated with fewer compliance problems ▪ Can be used with NRT ▪ Might be beneficial in patients with depression |
| DISADVANTAGES | <ul style="list-style-type: none"> ▪ Gum chewing may not be socially acceptable ▪ Gum is difficult to use with dentures ▪ Patients must use proper chewing technique to minimize adverse effects | <ul style="list-style-type: none"> ▪ Gastrointestinal side effects (nausea, hiccups, heartburn) might be bothersome | <ul style="list-style-type: none"> ▪ Patients cannot titrate the dose ▪ Allergic reactions to adhesive might occur ▪ 16-hour patch may lead to early morning nicotine cravings ▪ Patients with dermatologic conditions should not use the patch | <ul style="list-style-type: none"> ▪ Patients cannot titrate the dose ▪ Allergic reactions to adhesive might occur ▪ Patients with dermatologic conditions should not use the patch | | <ul style="list-style-type: none"> ▪ Nasal/throat irritation may be bothersome ▪ Dependence can result ▪ Patients must wait 5 minutes before driving or operating heavy machinery ▪ Patients with chronic nasal disorders or severe reactive airway disease should not use the spray | <ul style="list-style-type: none"> ▪ Initial throat or mouth irritation can be bothersome ▪ Cartridges should not be stored in very warm conditions or used in very cold conditions ▪ Patients with underlying bronchospastic disease must use the inhaler with caution | <ul style="list-style-type: none"> ▪ Seizure risk is increased (rare). ▪ Patients with anorexia or bulimia nervosa should not use bupropion ▪ Patients with a history of seizures or those taking medications that can lower the seizure threshold should not take bupropion |
| WEB-SITE | nicorette.quit.com | commitlozenge.quit.com | www.nicotrol.com | nicodermcq.quit.com | www.habitrol.com | www.nicotrol.com | www.nicotrol.com | www.zyban.com |
| COST/DAY ³ | 2 mg: \$2.53–\$5.16 (9 pieces) 4 mg: \$3.18–\$5.81 (9 pieces) | 2 mg: \$4.98 (9 pieces) 4 mg: \$5.31 (9 pieces) | \$3.17–\$3.70 (1 patch) | \$3.39–\$3.93 (1 patch) | \$2.10–\$2.94 (1 patch) | \$2.66 (8 doses) | \$4.76–\$6.07 (6 cartridges) | \$3.62–\$5.24 (2 tablets) |

¹ Marketed by GlaxoSmithKline.

² Marketed by Pfizer.

³ Average wholesale price from 2005 Drug Topics Redbook. Montvale, NJ: Medical Economics Company, Inc., December 2005.

Abbreviations: Hx, history; MAO, monoamine oxidase; NRT, nicotine replacement therapy; OTC, (over-the-counter) non-prescription product; Rx, prescription product.

For complete prescribing information, please refer to the manufacturers' package inserts.

Copyright © 1999-2006 The Regents of the University of California, University of Southern California, and Western University of Health Sciences. All rights reserved.